Farid Menaa
Farid Menaa
Associate Professor

Department of Oncology
Stem Cells and Nanomedicine Fluorotronics


2004 Ph.D.

Doctoral School “G2ID” & CEA



1998 M.Sc.

School of Medicine & INSERM



1997 B.Sc. School of Medicine of Paris France  
1996 B.Sc. Institute of Technology (IUT) Caen France



Dr. Farid Menaa, is a French citizen, proficient in various languages (fluency in French, English, Portuguese; acceptable knowledge in Spanish, German and Arabic) and has lived in four countries within two continents. Dr. Menaa is an experienced and skilled inter- and multi-disciplinary professional.
Dr. Menaa earned his degrees mainly from France (Paris) with high distinctions from prestigious universities and institutions. He holds a Bsc. Eng. Bio, Bsc. Physiology and Cell Biology, Msc. Genetics/Molecular and Cell Biology, Msc Gerontology/Genetics, PhD Gerontology/Genetics/Radiation Oncology, EMBA Entrepreneurship, three international post-doctoral specialties (i.e. Oncology and drug discovery; Dermato-oncology and stem cells research; Hematology and genomics).
Dr. Menaa assumed different positions as a Teacher, Principal Investigator, Executive Director, Consultant, Advisor, Editor, Reviewer, Event Organizer or Entrepreneur, and he was recently selected for “Who´s is Who in the World”. His mentors include world-renowned professionals such as Prof. Dr. Axel Kahn (MD, PhD – France), Prof. Dr. Juergen C. Becker (MD, PhD – Germany), and Prof. Dr. Fernando Ferreira Costa (MD, PhD – Brazil).
Thereby, as a CFR and LNCC awarded investigator, he earned his doctorate of gerontology and oncology in 2003 with highest distinction from Sorbonne?university of Paris 7 & Nuclear Energy Authority/Ministry of Defence (Paris, France) after identifying new human genes involved in the radio-modulation of mammalian cancer cells while contributing with projects related to DNA repair systems.
Then, as NIH fellow (2004-2007) in oncology and drug discovery, he pursued his career at Sidney Kimmel Cancer Center\Sanford-Burnham Medical Research Institute (San Diego, California, USA) where he pioneered a paradigmatic DNA-damage signaling pathway while contributing to other projects associated with cell cycle and proteolysis systems.
Subsequently, as a DFG fellow (2007-2009) in dermatology, dermato-immunology and dermato- oncology at the University of Wuerzburg (Wuerzburg, Bavaria, Germany), he discovered a crucial association between skin cancer stem cells, diagnosis and prognosis.
Recently, as a FAPESP fellow (2010-2012) in hematology and genomics at the State University of Campinas (UNICAMP) (Campinas, São Paulo, Brazil), he pioneered the identification of new genomic variants of stroke in adult patients with sickle cell anemia.
Further, Dr. Menaa is experienced with teaching and served for more than five years as editor and/or reviewer in a large number of esteemed journals worldwide (>80) such as: Physical Chemistry Chemical Physics (RSC), Organic and Biomolecular Chemistry (RSC), Current Medicinal Chemistry (Bentham Science), Current Organic Chemistry (Bentham Science), Current Drug Therapy (Bentham Science), Journal of Biomedicine and Biotechnology (Hindawi), International Journal of Nanomedicine (Dovepress), Journal of Regenerative Medicine (Sci Technol), Journal of Nanomaterials & Molecular Nanotechnology (Sci Technol), Journal of Biomaterials and Nanobiotechnology (Scirp), Journal of Nanomedicine and Biotherapeutics Discovery (OMICS), European Journal of Nutrition (Springer), Journal of Business & Financial Affairs (OMICS), Journal of Economics and International Business Management (Sciencewebpublishing). Dr. Menaa is/was also a member of several prestigious medical and scientific societies (e.g. AACR, ASCB, IRSCC, SPIE, RSC, ACS, ASH, ASHG, AAPS).
Importantly, Dr. Menaa has the ability to develop national and international scientific collaborations with academic (> 10 worldwide universities), governmental (e.g. FDA, ANVISA, AFSSA/ANSESS) and industrial organizations (e.g. Fluorotronics Inc., California Innovation group, Inc; Exiquon, Pfizer, Novartis).
Besides his academic achievements, Dr. Menaa has also a long-lasting experience (> 7 years with pharmaceutical, chemical, biotechnology and nanotechnology companies (e.g. Guerbet, HMR/Aventis, Fluorotronics) where he developed more than twenty R&D and business projects (e.g. stem cells, oncology, anti-aging medicine, nutrition and food technology, pharmaceutical sciences, biochemistry, microbiology, physico-chemistry); Many of them have been published. For instance, he was a consultant, director, coacher, head of laboratory/supervisor, business and scientific advisory boards member, chief scientific officer and R&D&I executive vice-president at Fluorotronics, Inc., San Diego, CA, USA, a nanotechnology and fluorine chemical company (2006-2012). Dr. Menaa is co- founding Bionanomics, an innovative biotechnology and pharmaceutical company at the interface of nanotechnology, nanomedicine and nanopharmacy. Dr. Menaa is also founding the multi- and inter- disciplinary alliance for the advancement of Medicine, Science and Technology, namely OHGGENIO (Oncology-Hematology-Gerontology-Genetics-Nanomedicine-Innovation).
Dr. Menaa´s main current focuses are related to preventive, personalized, translational, integrative, green and nano-based medicine, especially in the areas of oncology, regenerative medicine and gerontology, in order to prevent, implement early diagnosis, and develop efficient and safer therapy.
Dr. Menaa has authored more than 70 publications (including peer-reviewed ISI research and review articles, books, book chapters, conference proceedings, pending patents), mostly as first author and/or corresponding author. Several articles are also on the way to get (re-)submitted. Dr Menaa is getting highly cited (> 400 citations) and is the recipient of several awards (e.g. Scholarships, Fellowships).
Moreover,  Dr.  Menaa  was  the  leading  organizer  of  the  “Target  Meeting´s  1st    World
Nanomedicine and Nanobiotechnology Online Conference” (http://www.targetmeeting.com; 2013), co-organizer of two “Nanomaterials Conference” (Beijing, China; 2013, Shenzhen, China; 2014), member of the technical committee of the  “3rd ScienceOne Conference on Drug Discovery and Development” (Dubai, UAE; 2014). Dr. Menaa is regularly invited as a chairman and/or renowned speaker to reputed world congresses and organizations (> 100), where he is offering speeches in various areas of medicine, sciences and technology. He has participated to over 250 events related to Medecine, Sciences, Technology and Business Administration, and has produced >150 abstracts, some indexed in good impact factor journals (e.g. Tissue Engineering Part A; Current Medicinal Chemistry).

During his spare time, Dr. Menaa enjoys family, arts, sports and travelling.

Research Interest


Professional Activities:



  1. Sharif A, Akhtar N, Khan  MS, Menaa A, Menaa B, Khan BA, Menaa F. Formulation  and evaluation on human skin of a water-in-oil emulsion containing Muscat hamburg black grape seed extract**. Int J Cosmet Sci. 2015 ; 37(2):253-8. (**featured article)
  2. Cruz PR, Lira RP, Pereira Filho SA, Souza BB, Mitsuushi FN, Menaa F, Fertrin KY, Vasconcellos JP, Conran N, Costa FF, Melo MB. Increased circulating PEDF and low sICAM-1 are associated with sickle cell retinopathy. Blood Cells Mol Dis. 2015; 54(1):33-7.
  3. Menaa F, Abdelghani A, Menaa B. Graphene nanomaterials as biocompatible and conductive scaffolds for stem cells: impact for tissue engineering and regenerative medicine. J Tissue Eng Regen Med. 2014 Jun 11.
  4. Shahrokhi S, Daneshmandi S, Menaa F. Tumor necrosis factor-α/CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice. Hum Gene Ther. 2014 ;25(3):240-53.
  5. Menaa F. Stroke  in  sickle  cell  anemia  patients:  A  need  for  multidisciplinary  approaches.
  6. Atherosclerosis. 2013; 229(2):496-503.
  7. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? J Skin  Cancer.
  8. 2013; 2013:735282.
  9. Menaa F, Menaa A, Tréton J, Menaa B. Technological approaches to minimize industrial trans fatty acids in foods. J Food Sci. 2013; 78(3):R377-86.
  10. Menaa F, Menaa A, Menaa B, Tréton J. Trans-fatty acids, dangerous bonds for health? A background review paper of their use, consumption, health implications and regulation in France**. Eur J Nutr. 2013; 52(4):1289-302. (**featured article)
  11. Shahrokhi S*, Menaa F*, Alimoghaddam K, McGuckin C, Ebtekar M. Insights and hopes in umbilical cord blood stem cell transplantations. J Biomed Biotechnol. 2012; 2012:572821. (*equal contribution)
  12. Mahamuni SP, Khose RD, Menaa F, Badole SL. Therapeutic approaches to drug targets in hyperlipidemia. BioMedicine. 2012; 2(4):137-146.
  13. Menaa F, Menaa B. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma**. Curr Med Chem. 2012; 19(34):5854-62. (**featured article)
  14. Menaa F, Braghini CA, Vasconcellos JP, Menaa B, Costa VP, Figueiredo ES, Melo MB. Keeping an eye on myocilin: a complex molecule associated with primary open-angle glaucoma susceptibility. Molecules. 2011; 16(7):5402-21.
  15. Menaa F, Menaa B, Sharts O. Development of carbon-fluorine spectroscopy for pharmaceutical and biomedical applications**. Faraday Discuss. 2011; 149:269-78; discussion 333-56. (**featured article)
  16. Menaa B, Montoneri C, Menaa F, Montoneri E, Boffa V and Sharts N.O: Protein helical structure enhancement in biocompatible fluoro-phosphanate-based nanoporous silica glasses assessed by circular dichroism spectroscopy. Int. J. Nanotechnol. 2011; 8:471-91.
  17. Guimarães CA, Menaa F, Menaa B, Quenca-Guillen J, Matos J do R, Mercuri LP, Briaz AB, Rossetti   FC,   Kedor-Hackmann   ER   and   Santoro   MIRM.   Comparative   Physical-chemical
  18. characterization of encapsulated isotretinoin products assessed by particle size distribution and thermal behavior analysis. Thermochimica Acta. 2010; 505:73-8.
  19. Menaa B, Menaa F, Guimarães CA and Sharts O: Silica-based nanoporous sol-gel glasses: from bioencapsulation to protein folding studies**. Int. J. Nanotechnol. 2010; 7(1):1-45. (**featured article)
  20. Boucharaba A, Guillet B, Menaa F, Hneino M, van Wijnen AJ, Clézardin P, Peyruchaud O. Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. Oncol Res. 2009;18(4):173-84.
  21. Menaa B, Miyagawa Y, Takahashi M, Herrero M, Rives V, Menaa F, Eggers DK. Bioencapsulation of apomyoglobin in nanoporous organosilica sol-gel glasses: influence of the siloxane network on the conformation and stability of a model protein. Biopolymers. 2009; 91(11):895-906.
  22. Menaa F, Houben R, Eyrich M, Broecker EB, Becker JC, Wischhusen J. Stem cells, melanoma and cancer stem cells: the good, the bad and the evil? G Ital Dermatol Venereol. 2009; 144(3):287-96.
  23. Houben R, Wischhusen J, Menaa F, Synwoldt P, Schrama D, Bröcker EB, Becker JC. Melanoma stem cells: targets for successful therapy? J Dtsch Dermatol Ges. 2008; 6(7):541-6.
  24. Masson C*, Menaa F*, Pinon-Lataillade G, Frobert Y, Chevillard S, Radicella JP, Sarasin A, Angulo JF. Global genome repair is required to activate KIN17, a UVC-responsive gene involved in DNA replication. Proc Natl Acad Sci U S A. 2003; 100(2):616-21. (*equal contribution).
  25. Masson C, Menaa F, Pinon-Lataillade G, Frobert Y, Radicella JP, Angulo JF. Identification of KIN (KIN17), a human gene encoding a nuclear DNA-binding protein, as a novel component of the TP53-independent response to ionizing radiation. Radiat Res. 2001; 156(5 Pt 1):535-44.


Autoimmune Journal Flyer